Composite endpoints in clinical trials

Ignacio Ferreira-González, Pablo Alonso-Coello, Ivan Solà, Valeria Pacheco-Huergo, Antònia Domingo-Salvany, Jordi Alonso, Victor Manuel Montori, Gaietà Permanyer-Miralda

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Composite endpoints are often used in clinical trials, especially in the cardiovascular area. Decreases in sample size requirements, ability to assess the net effect of an intervention and to avoid bias in presence of competing risk are the most cited advantages for their use. However, there is a risk of misinterpretation when heterogeneity among components with respect to either importance, number of events, or magnitude of treatment effect exist. In the following review we present a conceptual discussion about the rationale and interpretation of such variables. Also, a user's friendly guide to interpret the results of clinical trials based on composite endpoints is presented. We also present an empirical study that provides evidence of the use of misleading composite endpoints in cardiovascular clinical trials.

Original languageEnglish (US)
Pages (from-to)283-290
Number of pages8
JournalRevista Espanola de Cardiologia
Volume61
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Clinical Trials
Sample Size

Keywords

  • Clinical trials
  • Composite endpoints
  • Heterogeneity

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Medicine(all)

Cite this

Ferreira-González, I., Alonso-Coello, P., Solà, I., Pacheco-Huergo, V., Domingo-Salvany, A., Alonso, J., ... Permanyer-Miralda, G. (2008). Composite endpoints in clinical trials. Revista Espanola de Cardiologia, 61(3), 283-290. https://doi.org/10.1157/13116656

Composite endpoints in clinical trials. / Ferreira-González, Ignacio; Alonso-Coello, Pablo; Solà, Ivan; Pacheco-Huergo, Valeria; Domingo-Salvany, Antònia; Alonso, Jordi; Montori, Victor Manuel; Permanyer-Miralda, Gaietà.

In: Revista Espanola de Cardiologia, Vol. 61, No. 3, 03.2008, p. 283-290.

Research output: Contribution to journalArticle

Ferreira-González, I, Alonso-Coello, P, Solà, I, Pacheco-Huergo, V, Domingo-Salvany, A, Alonso, J, Montori, VM & Permanyer-Miralda, G 2008, 'Composite endpoints in clinical trials', Revista Espanola de Cardiologia, vol. 61, no. 3, pp. 283-290. https://doi.org/10.1157/13116656
Ferreira-González I, Alonso-Coello P, Solà I, Pacheco-Huergo V, Domingo-Salvany A, Alonso J et al. Composite endpoints in clinical trials. Revista Espanola de Cardiologia. 2008 Mar;61(3):283-290. https://doi.org/10.1157/13116656
Ferreira-González, Ignacio ; Alonso-Coello, Pablo ; Solà, Ivan ; Pacheco-Huergo, Valeria ; Domingo-Salvany, Antònia ; Alonso, Jordi ; Montori, Victor Manuel ; Permanyer-Miralda, Gaietà. / Composite endpoints in clinical trials. In: Revista Espanola de Cardiologia. 2008 ; Vol. 61, No. 3. pp. 283-290.
@article{bb97064eb4c34e90b32ee6e5485dc86f,
title = "Composite endpoints in clinical trials",
abstract = "Composite endpoints are often used in clinical trials, especially in the cardiovascular area. Decreases in sample size requirements, ability to assess the net effect of an intervention and to avoid bias in presence of competing risk are the most cited advantages for their use. However, there is a risk of misinterpretation when heterogeneity among components with respect to either importance, number of events, or magnitude of treatment effect exist. In the following review we present a conceptual discussion about the rationale and interpretation of such variables. Also, a user's friendly guide to interpret the results of clinical trials based on composite endpoints is presented. We also present an empirical study that provides evidence of the use of misleading composite endpoints in cardiovascular clinical trials.",
keywords = "Clinical trials, Composite endpoints, Heterogeneity",
author = "Ignacio Ferreira-Gonz{\'a}lez and Pablo Alonso-Coello and Ivan Sol{\`a} and Valeria Pacheco-Huergo and Ant{\`o}nia Domingo-Salvany and Jordi Alonso and Montori, {Victor Manuel} and Gaiet{\`a} Permanyer-Miralda",
year = "2008",
month = "3",
doi = "10.1157/13116656",
language = "English (US)",
volume = "61",
pages = "283--290",
journal = "Revista Espanola de Cardiologia",
issn = "0300-8932",
publisher = "Ediciones Doyma, S.L.",
number = "3",

}

TY - JOUR

T1 - Composite endpoints in clinical trials

AU - Ferreira-González, Ignacio

AU - Alonso-Coello, Pablo

AU - Solà, Ivan

AU - Pacheco-Huergo, Valeria

AU - Domingo-Salvany, Antònia

AU - Alonso, Jordi

AU - Montori, Victor Manuel

AU - Permanyer-Miralda, Gaietà

PY - 2008/3

Y1 - 2008/3

N2 - Composite endpoints are often used in clinical trials, especially in the cardiovascular area. Decreases in sample size requirements, ability to assess the net effect of an intervention and to avoid bias in presence of competing risk are the most cited advantages for their use. However, there is a risk of misinterpretation when heterogeneity among components with respect to either importance, number of events, or magnitude of treatment effect exist. In the following review we present a conceptual discussion about the rationale and interpretation of such variables. Also, a user's friendly guide to interpret the results of clinical trials based on composite endpoints is presented. We also present an empirical study that provides evidence of the use of misleading composite endpoints in cardiovascular clinical trials.

AB - Composite endpoints are often used in clinical trials, especially in the cardiovascular area. Decreases in sample size requirements, ability to assess the net effect of an intervention and to avoid bias in presence of competing risk are the most cited advantages for their use. However, there is a risk of misinterpretation when heterogeneity among components with respect to either importance, number of events, or magnitude of treatment effect exist. In the following review we present a conceptual discussion about the rationale and interpretation of such variables. Also, a user's friendly guide to interpret the results of clinical trials based on composite endpoints is presented. We also present an empirical study that provides evidence of the use of misleading composite endpoints in cardiovascular clinical trials.

KW - Clinical trials

KW - Composite endpoints

KW - Heterogeneity

UR - http://www.scopus.com/inward/record.url?scp=44449156429&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=44449156429&partnerID=8YFLogxK

U2 - 10.1157/13116656

DO - 10.1157/13116656

M3 - Article

VL - 61

SP - 283

EP - 290

JO - Revista Espanola de Cardiologia

JF - Revista Espanola de Cardiologia

SN - 0300-8932

IS - 3

ER -